证券代码：301130 证券简称：西点药业 公告编号：2026-005 吉林省西点药业科技发展股份有限公司 关于回购公司股份方案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 （7）回购股份的实施期限：自公司董事会审议通过本次回购股份方案之日 起 12 个月内。 重要内容提示： 1、回购方案的主要内容 （1）回购股份的种类：公司已发行的人民币普通股（A 股）股票。 （2）回购股份的用途：用于实施员工持股计划或股权激励，如公司未能在 股份回购实施完成之后 36 个月内将已回购股份使用完毕，尚未使用的已回购股 份将被注销。如国家对相关政策做调整，则按调整后的政策执行。 （3）回购股份的资金总额：不低于人民币 2,500 万元（含），不超过人民 币 5,000 万元（含）。具体回购资金总额以回购期满时实际回购股份使用的资金 总额为准。 （4）回购股份的价格：不超过人民币 42.00 元/股（含）。 （5）回购股份的数量：按照回购金额上限 5,000 万元、回购价格上限 42.00 元/股测算，预计回购股份数量为 1,190,476 股（含），约占已发行 A ...

证券代码：301130 证券简称：西点药业 公告编号：2026-002 吉林省西点药业科技发展股份有限公司 第八届董事会第十四次会议决议公告 公司高级管理人员、保荐代表人列席了会议。 会议的召开符合《中华人民共和国公司法》和《公司章程》的规定，会议合 法有效。 二、会议审议情况 经与会董事认真审议并表决，一致通过了如下事项： （一）审议通过《关于使用部分闲置募集资金进行现金管理及使用部分闲 置自有资金进行现金管理和委托理财的议案》 为使公司资金效益最大化，董事会同意： 公司在确保募集资金投资项目建设正常进行和资金安全的前提下，使用额度 不超过人民币 7,500 万元的部分闲置募集资金（含超募资金）进行现金管理；公 司及全资子公司在确保不影响公司日常经营的前提下，使用额度不超过人民币 2.5 亿元的部分闲置自有资金进行现金管理和委托理财。前述额度自董事会审议 通过之日起 12 个月内有效。在上述额度和期限内，资金可循环滚动使用。董事 会授权公司管理层在上述额度及期限内签署相关合同文件，公司财务部门负责组 织实施。授权期限与上述期限一致。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、 ...

证券代码：301130 证券简称：西点药业 公告编号：2026-007 吉林省西点药业科技发展股份有限公司 关于公司硫酸氨基葡萄糖胶囊获得药品注册证书的公告 剂型：胶囊剂 规格：0.25g（按硫酸氨基葡萄糖计）或 0.314g（按硫酸氨基葡萄糖氯化钠 计） 注册标准编号：YBH27792025 注册分类：化学药品 4 类 药品批准文号：国药准字 H20255903 上市许可持有人：吉林省西点药业科技发展股份有限公司 上市许可持有人地址：吉林省磐石经济开发区西点大街 777 号 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 吉林省西点药业科技发展股份有限公司（以下简称"公司"）于近日收到国 家药品监督管理局（以下简称"国家药监局"）签发的硫酸氨基葡萄糖胶囊《药 品注册证书》。现将相关情况公告如下： 一、药品的基本情况 药品名称：硫酸氨基葡萄糖胶囊 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。同意本品按（甲类） 非处方药管理。质量标准、说明书、标签及生产工艺照所附执行。药品生产企业 应当 ...

国泰海通证券股份有限公司 关于吉林省西点药业科技发展股份有限公司 使用部分闲置募集资金进行现金管理的核查意见 国泰海通证券股份有限公司（以下简称"国泰海通"或"保荐机构"）作为 吉林省西点药业科技发展股份有限公司（以下简称"西点药业"或"公司"）首次公 开发行股票并在创业板上市的保荐机构，根据《证券发行上市保荐业务管理办法》 《上市公司募集资金监管规则》《深圳证券交易所上市公司自律监管指引第 2 号 ——创业板上市公司规范运作》《深圳证券交易所创业板股票上市规则》等有关 法律法规和规范性文件的要求，就公司使用部分闲置募集资金（含超募资金）进 行现金管理的事项进行了审慎核查，并发表如下核查意见: 一、募集资金基本情况 经中国证券监督管理委员会《关于同意吉林省西点药业科技发展股份有限公 司首次公开发行股票注册的批复》（证监许可〔2022〕5 号）同意注册，公司首 次公开发行人民币普通股（A 股）股票 2,020.0986 万股，每股发行价格为人民币 22.55 元，募集资金总额为人民币 45,553.22 万元，扣除各项发行费用后实际募集 资金净额为人民币 39,093.31 万元。上述募集资金到位情况已经大华会 ...

Core Viewpoint - The company has approved the use of idle raised funds and self-owned funds for cash management and entrusted financial management, ensuring that the normal operation of investment projects and fund safety are prioritized. Group 1: Fund Management Approval - The company convened the 10th meeting of the 8th Board of Directors and the 10th meeting of the 8th Supervisory Board on January 20, 2025, to approve the proposal for cash management using idle raised funds and self-owned funds, with a limit of up to RMB 100 million for raised funds and RMB 150 million for self-owned funds [1][2]. Group 2: Redemption of Financial Products - The company and its wholly-owned subsidiaries have redeemed all principal and income from cash management products and entrusted financial management as of the announcement date [1][7]. Group 3: Approval Process - The proposal for cash management has been approved by both the Board of Directors and the Supervisory Board, with clear consent from the supervisory board and the sponsor institution [2]. Group 4: Financial Impact - As of the announcement date, the company has not exceeded the authorized limit for cash management using idle raised funds and self-owned funds, with a balance of RMB 0 for both categories [7]. Group 5: Documentation of Financial Products - The company has provided documentation for various redeemed financial products, including structured deposits and asset management plans, indicating a diversified approach to cash management [8][9].

Core Viewpoint - The company has approved the use of idle raised funds and self-owned funds for cash management and entrusted financial management, with a total limit of up to RMB 2.5 billion, ensuring the normal operation of investment projects and fund safety [2]. Group 1: Fund Management Approval - The company held the eighth board meeting and the eighth supervisory board meeting on January 20, 2025, where it approved the use of idle raised funds not exceeding RMB 1.0 billion and idle self-owned funds not exceeding RMB 1.5 billion for cash management and entrusted financial management [2][3]. - The investment products chosen are characterized by high safety, good liquidity, and a maturity period not exceeding 12 months [2]. Group 2: Redemption of Financial Products - Recently, the company and its wholly-owned subsidiaries have redeemed all principal and income from cash management and entrusted financial products [2][6]. - The company has disclosed detailed information regarding the redemption of these financial products in various announcements [2]. Group 3: Approval Process - The proposal for using idle funds for cash management was approved by both the board of directors and the supervisory board, with clear consent from the supervisory board and the sponsor institution [3]. Group 4: Financial Impact - As of the announcement date, the company has no outstanding balance of idle raised funds for cash management, and the total usage of self-owned funds for cash management and entrusted financial management is also zero, remaining within the authorized limits set by the board [6].

关于使用闲置募集资金及自有资金进行现金管理和委托理财 到期赎回的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 吉林省西点药业科技发展股份有限公司（以下简称"公司"）于 2025 年 1 月 20 日召开第八届董事会第十次会议、第八届监事会第十次会议，分别审议通 过了《关于使用部分闲置募集资金进行现金管理及使用部分闲置自有资金进行现 金管理和委托理财的议案》，同意公司在确保募集资金投资项目建设正常进行和 资金安全的前提下，使用额度不超过人民币 1.0 亿元的部分闲置募集资金（含超 募资金）进行现金管理，公司及全资子公司在确保不影响公司日常经营的前提下， 使用额度不超过人民币 1.5 亿元的部分闲置自有资金进行现金管理和委托理财， 用于购买安全性高、流动性好、期限不超过 12 个月的短期投资理财产品。使用 期限自董事会审议通过之日起 12 个月内有效。在上述额度和期限内，资金可循 环滚动使用。具体内容详见公司在巨潮资讯网上披露的《关于使用部分闲置募集 资金进行现金管理及使用部分闲置自有资金进行现金管理和委托理财的公告》。 近日，公司及全资子公司使用部分闲置 ...

Core Viewpoint - The report highlights the growth of industrial enterprises in Jilin Province, indicating a positive trend in the industrial sector with a year-on-year increase in the number of enterprises [1] Group 1: Company Information - Listed companies mentioned include Liyuan Co., Ltd. (002501), ST Jinhong (000669), Changchun Gas (600333), Quanyuan Spring (600189), Tonghua Jinma (000766), Xidian Pharmaceutical (301130), Jilin Carbon Valley (836077), Zhongyan Co., Ltd. (688716), Zhiyuan New Energy (300985), FAW Jiefang (000800), Jilin Expressway (601518), and Jilin Electric Power (000875) [1] Group 2: Industry Statistics - As of January-November 2025, the number of industrial enterprises in Jilin Province reached 3,539, an increase of 142 compared to the same period last year, representing a growth rate of 4.18% [1] - The proportion of Jilin's industrial enterprises accounts for 0.67% of the national total [1] Group 3: Research and Consulting - Zhiyan Consulting is identified as a leading industry consulting firm in China, specializing in deep industry research reports, business plans, feasibility studies, and customized services [1] - The firm emphasizes its commitment to providing comprehensive industry solutions to empower investment decisions [1]

Group 1 - The core viewpoint of the news is that Xidian Pharmaceutical's stock performance and financing activities indicate a relatively high level of market engagement, despite a slight decline in stock price and financial metrics [1][2] Group 2 - On December 23, Xidian Pharmaceutical's stock price decreased by 0.31%, with a trading volume of 16.9772 million yuan. The financing buy amount was 1.9865 million yuan, while the financing repayment was 2.8608 million yuan, resulting in a net financing buy of -0.8743 million yuan [1] - As of December 23, the total balance of margin trading for Xidian Pharmaceutical was 123 million yuan, which accounts for 5.53% of its circulating market value, indicating a high level compared to the past year [1] - The company has not engaged in any short selling activities on December 23, with a short selling balance of 0.00 shares, placing it in the 90th percentile of the past year [1] Group 3 - As of September 30, the number of shareholders for Xidian Pharmaceutical was 7,863, a decrease of 2.91% from the previous period, while the average circulating shares per person increased by 2.97% to 7,426 shares [2] - For the period from January to September 2025, Xidian Pharmaceutical reported an operating income of 189 million yuan, a year-on-year decrease of 1.89%, and a net profit attributable to the parent company of 33.1464 million yuan, down 2.70% year-on-year [2] - Since its A-share listing, Xidian Pharmaceutical has distributed a total of 63.3372 million yuan in dividends, with 52.8326 million yuan distributed over the past three years [2]

证券代码：301130 证券简称：西点药业 公告编号：2025-077 吉林省西点药业科技发展股份有限公司 关于使用闲置募集资金进行现金管理到期赎回并 继续进行现金管理的公告 三、审批程序 《关于使用部分闲置募集资金进行现金管理及使用部分闲置自有资金进行 现金管理和委托理财的议案》已经第八届董事会第十次会议、第八届监事会第十 次会议审议通过，公司监事会和保荐机构均发表了明确同意的意见。本次购买现 金管理的产品额度和期限均在审批范围内，无需另行提交公司董事会及股东会审 议。 四、关联关系说明 公司与上述银行不存在关联关系。 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 吉林省西点药业科技发展股份有限公司（以下简称"公司"）于 2025 年 1 月 20 日召开第八届董事会第十次会议、第八届监事会第十次会议，分别审议通 过了《关于使用部分闲置募集资金进行现金管理及使用部分闲置自有资金进行现 金管理和委托理财的议案》，同意公司在确保募集资金投资项目建设正常进行和 资金安全的前提下，使用额度不超过人民币 1.0 亿元的部分闲置募集资金（含超 募资金）进行现金管理，公 ...